Trimel Pharmaceuticals - Seeking positive EBITDA with Estrace
06 Août 2014 - 6:27AM
InvestorsHub NewsWire
Trimel
(TSX:TRL)
has acquired Canadian rights to Estrace (oral 17-beta estradiol)
for C$44.5m from Shire. This profitable asset, with US$9-10m in
annual sales, complements Trimel's existing hormone replacement
pipeline. The transaction fits with the goal to become EBITDA
positive within 12-18 months, although future Natesto-related
revenue (upon completion of a partnership transaction) will be the
key driver towards this objective.
Trimel
is a Canadian specialty pharmaceutical company. Natesto and Tefina
deliver testosterone through a bio-adhesive nasal gel drug delivery
technology platform, for male hypogonadism and female orgasmic
disorder (FOD), respectively. Estrace is being marketed for HRT in
Canada.
To view the full report, click on the following link: http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals-
To view all of Edison's recently pubished research, click here.
Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Trilogy International Partners Inc (Toronto Stock Exchange): 0 recent articles
Plus d'articles sur Trimel Pharmaceuticals Corp